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Although amiodarone is effective in the treatment of
ventricular arrhythmias, it is associated with serious toxic
effects. In addition, the prognosis of patients with ma-
lignant ventricular arrhythmias and coronary artery dis-
ease treated with amiodarone remains poor. The sur-
vival of 54 consecutive patients with angiographically
documented coronary artery disease and symptomatic
ventricular tachycardia or ventricular fibrillation treated
with amiodarone was compared with that of 5, 125 med-
ically treated patients with coronary artery disease. The
amiodarone group was older, with worse left ventricular
function and more peripheral and cerebrovascular dis-
ease.
The I year survival probability was 0.73 for the amio-
darone group and 0.94 for the control coronary artery
Amiodarone is an antiarrhythmic drug that is often effective
in the treatment of refractory ventricular arrhythmias (1-16).
Initial investigations (1-4) reported few toxic effects and a
very high rate of success in preventing the recurrence of
ventricular tachycardia and ventricular fibrillation. Further
experience (5-7), however, has demonstrated lower anti-
arrhythmic efficacy and a higher incidence of significant
toxicity than was previously appreciated. Because many
patients treated with amiodarone for life-threatening ven-
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disease group. At 2 years of follow-up, the survival prob-
abilities were 0.60 and 0.90 for the amiodarone and the
control group, respectively. When the survival curves
were adjusted for group differences in baseline prog-
nostic characteristics (integrated as a previously pub-
lished hazard score), there was no difference in the prog-
nosis of the two groups.
These findings suggest that treatment with amioda-
rone of malignant ventricular arrhythmias associated
with coronary artery disease maintains patients on an
underlying survival curve determined by the degree of
myocardial dysfunction, clinical characteristics and
coronary anatomy, and that amiodarone does not have
a deleterious effect on survival.
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tricular arrhythmias have poor left ventricular function and
severe coronary artery disease, we addressed the question
of how the survival of these patients compares with that of
a control group of patients with a similar degree of coronary
artery disease and left ventricular performance. Our findings
indicate that patients with coronary artery disease treated
with amiodarone for malignant ventricular arrhythmias have
a survival curve nearly identical to that of the control group.
Methods
Study patients. One hundred twenty patients were treated
with amiodarone for life-threatening ventricular arrhythmias
at our medical center between August 1979 and September
1985. Patients were excluded if they had primary cardio-
myopathy, congenital, valvular or no structural heart dis-
ease, prior coronary artery bypass or ventricular arrhythmia
surgery or had been evaluated by coronary arteriography
long before the initiation of amiodarone therapy. There re-
mained 54 patients with '2:.75% luminal diameter stenosis
of at least one major coronary artery proved by coronary
arteriography within 3 months of beginning treatment with
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amiodarone for ventricular tachycardia or ventricular fi-
brillation. These patients constituted the study group.
Clinical arrhythmias and amiodarone dosing. The
clinical arrhythmia was sustained ventricular tachycardia
(>30 seconds or requiring cardioversion) in 44 patients,
symptomatic nonsustained ventricular tachycardia (5 beats
to 30 seconds) in 5 and ventricular fibrillation in 5. All
patients had inducible ventriculartachycardia or ventricular
fibrillation at electrophysiologic study and had not re-
sponded to multiple trials of conventional antiarrhythmic
drugs. Amiodarone was administered orally in a loading
dose of 1,200 mg/day for 4 days, 800 mg/day for 4 days
and 600 mg/dayfor 2 days, followed by a maintenance dose
of 400 to 600 mg/day.
Control coronary artery disease group. The control
group comprised5,125 medically treatedpatientswithcoro-
nary artery disease demonstrated by cardiac catheterization
at Duke University MedicalCenter between 1969 and 1984.
Our patient population and computerized information sys-
tem have been previouslydescribed in detail (17). The con-
trolgroupexcludedpatientswithvalvularor congenitalheart
disease, prior coronary artery surgery or prior percutaneous
transluminal coronary angioplasty. All patients had '.2.75%
stenosis of the luminal diameter of at least one major coro-
nary artery (18,19).
Data collection. In both the study and control groups,
baselineclinical information was collected prospectively at
the time of catheterization as previously described (17,18).
Follow-up information was obtained at 6 and 12 months
after initial catheterization and annually thereafter for the
control group. Follow-up in the control group was 98%
complete (18). Patients in the amiodarone group were fol-
lowed up by a clinical visit every 3 months; follow-up in
this group was 100% complete.
Data analysis. Differences inclinicalandcatheterization
variables between the amiodarone group and the control
coronary disease group were examined by the Wilcoxon
rank-sum test for continuous variables and the chi-square
statistic for discrete variables (20). A hazard score was
calculated for each patient from the baseline clinical and
Table 1. Baseline Clinical and Angiographic Characteristics of the Two Patient Groups
Arniodarone Control
(n = 54) (n = 5125) P Yalue
Age (yr)* 603 ± 8.6 53.7 ± 9.3 0.0001
% Male 88.9 81.4 0.2161
Stable angina 59.3 50.4 0.0001
Progressive angina 40.7 49.6
Angina frequency (episodes/week)" 2.7 ± 4.0 9.9 ± 13.9 0.0001
NYHA CHF class
I 5.6 1.5 _________
2 24.1 3.4 0.0001
3 24.1 2.6 ______
4 16.7 2.2
History of MI 90.7 51.3 0.0001
Peripheral vascular disease 29.6 6.3 0.0001
Cerebrovascular disease 13.0 3.4 0.0001
S, gallop 38.9 6.2 0.0001
Q waves 1'8.9 39.2 0.0001
LBBB 20.4 I.7 0.0001
RBBB 7.4 2.1 0.0262
IYCO 33.3 3.6 0.0001
Cardiomegaly 79.6 13.9 0.0001
Number of diseased vessels
I 27.8 23.5 ____
2 33.3 29.6 _____ 0.4918
3 31'.9 469
Mean % LAD stenosis* 80.7 ± 32.8 78. I ± 29.1 0.0768
Mean % LMCA stenosis" 5.6 ± 18.6 12.2 ± 25.3 0.0143
Ejection fraction* 31.6 ± 14.1 52.1 ± 14.1 0.0001
*Yalues are mean ± SO. All other values are percents. IYCO = intraventricular conduction disturbance;
LAD = left anterior descending coronary artery; LBBB = left bundle branch block; LMCA = left main
coronary artery; MI = myocardial infarction; NYHA CHF class = New York Heart Association functional
congestive heart failure classification; RBBB = right bundle branch block.
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catheterization variables (Table I). The hazard score is a
single variable used to summarize the mortality risk for
medically treated patients with coronary artery disease on
the basis of previously described Cox regression analyses
in our patient population (18,21). The distribution of hazard
scores in the amiodarone and control groups was determined
by percentile ranking.
Survival estimatesfor the amiodarone and control groups
were determined using the product limit formulation of Ka-
plan and Meier (22). Because of marked differences in the
distribution of hazard scores between the two groups, sur-
vival was also compared after the control coronary artery
disease group was adjusted to have the same distribution of
hazard scores as did the amiodarone group. This was done
in a manner analogous to that used to determine age-adjusted
mortality rates in populations with different age structures.
However, instead of using age-specific death rates, hazard
score-specific death rates were determined. The range of
hazard scores was divided into 12 subgroups and subgroup-
specific mortality rates were determined in the control group.
The control group was then weighted to have the same
relative distribution of hazard scores as did the amiodarone
group.
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Figure 1. Distribution of hazard scores is shown for the control
population of medically treated patients with coronary disease
(CATH) and for patients with coronary artery disease and malig-
nant ventricular arrhythmias treated with amiodarone (AMIO). The
10th (lower dots), 25th (lower triangle), 50th (asterisk), 75th
(tipper triangle)and90th (upper dots) percentiles arenoted. The
amiodarone group is heavily weighted toward a higher hazard
score, which is a single variable summarizing prognostic clinical
and catheterization characteristics for medically treated patients
with coronary artery disease.
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Results
Patient characteristics. The baseline clinical and an-
giographic characteristics are shown in Table I for the two
groups. The amiodarone group was older, with a higher
prevalence of congestive heart failure, previous myocardial
infarction, electrocardiographic Q waves, third sound gal-
lop, cardiomegaly, intraventricular conduction abnormali-
ties, peripheral vascuiar disease and cerebrovascular dis-
ease. The meanejection fraction was 31.6% in the amiodarone
group and 52.1 % in the control coronary artery disease
group (p = 0.000 I). There was no significant difference in
the number of diseased vessels or the degree of left anterior
descending coronary artery stenosis between the groups
(p = 0.49). The baseline characteristics were summarized
into a single variable of risk for cardiovascular mortality,
the hazard score. The distribution of hazard scores is shown
in Figure I for the two groups. The group treated with
amiodarone was heavily weighted with higher hazard scores
(worse survival) (mean amiodarome group hazard score 1.28.
mean control group hazard score -0.43, p = 0.0001).
YEARS FOLLOW- UP
Figure 2. Kaplan-Meier empirical survival curves for the control
population ofmedically treated patients with coronary disease (CAD)
and for patients with coronary disease and malignant ventricular
arrhythmias treated with amiodarone. The 95% confidence limits
are indicated by the vertical bars.
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mias suggested high efficacy and few side effects, more
recent experience (5-7) has been less enthusiastic. For ex-
ample, Fogoros et al. (5) noted that only 28% of patients
were alive and free of arrhythmia recurrence at 2 years of
follow-up. Toxic effects occurred in 72.5% of patients.
Similarly, Greene et al. (6) reported that side effects oc-
curred in 93% of patients treated with amiodarone and that
discontinuation of therapy was required in 19% because of
drug toxicity. In the same report, 13% of patients had new
onset or worsening of congestive heart failure while re-
ceiving amiodarone. In addition to these concerns, amio-
darone, like other antiarrhythmic agents, has the potential
to exacerbate or induce ventricular arrhythmias and con-
duction disturbances (14).
Survival of amiodarone-treated patients. Because
amiodarone may produce both favorable and deleterious
effects, we have compared the survival rate of patients with
coronary artery disease and malignant ventricular arrhyth-
mias treated with amiodarone with that of a control group
with coronary artery disease. The amiodarone group was
much' 'sicker" than the control patients with coronary artery
disease in terms of baseline prognostic clinical and cathe-
terization characteristics that were summarized into an over-
all risk of mortality for cardiovascular death, the hazard
score. As anticipated, the observed survival of the amio-
darone group was far worse than that of the control popu-
lation of medically treated patients with coronary artery
disease. However, when differences in the hazard score
were adjusted for, the mortality rate of the amiodarone group
was nearly identical to that of other patients with coronary
artery disease. Because the hazard score does not include
clinically significant ventricular arrhythmias, the amioda-
rone group would be expected to be at greater risk for
cardiovascular mortality even after adjustment. This sug-
gests that amiodarone used in treatment of malignant ven-
tricular arrhythmias associated with coronary artery disease
maintains patients on an underlying survival curve deter-
mined by the degree of myocardial dysfunction, clinical
characteristics and coronary anatomy (I8). Our results do
not support the conclusion that amiodarone has a deleterious
effect on survival in these patients.
Limitations of study. The major limitation of this study,
as with others dealing with this group of critically ill pa-
tients, is the lack of a strict, randomized control group of
patients with ventricular arrhythmias not treated with amio-
darone (14). However, because all patients in the study
group had not responded to treatment with conventional
antiarrhythmic drugs, a randomized study design was not
feasible. Another limitation is the lack of detailed infor-
mation regarding ventricular arrhythmias in the control pop-
ulation.
Summary. Our findings suggest that patients with coro-
nary artery disease and malignant ventricular arrhythmias
who are treated with amiodarone have a mortality rate sim-
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Discussion
Amiodarone efficacy and toxicity. Although early re-
ports (1-4) of amiodarone therapy for ventricular arrhyth-
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Figure 3. The observedKaplan-Meier survivalcurvefor thegroup
of patients with coronary artery disease and malignant ventricular
arrhythmias treated with amiodarone iscompared withthe adjusted
survival curve of the control population of medically treated pa-
tients with coronaryartery disease (CAD). The control population
has been adjusted to have the same distribution of hazard scores
as in the amiodarone population.
Observed survival probability. The median duration
of follow-up for the amiodarone group was 1.1 years (range
0.03 to 4.9). The observed survival probability for the amio-
darone group was less than that in the medically treated
control coronary artery disease group at all follow-up times
(Fig. 2). The I year Kaplan-Meier survival estimate was
0.73 (±0.14, 95% confidence limits) in the amiodarone
group and 0.94 ± 0.01 in the control group. At 2 years of
follow-up, the survival probabilities were 0.60 ± 0.16 and
0.90 ± 0.01 for the amiodarone and the control group,
respectively.
Adjusted survival probability. After adjusting for dif-
ferences in the distribution of hazard scores, the survival
curve of the control group was nearly identical to that ob-
served in the amiodarone group (Fig. 3). The adjusted I
year survival in the control group was 0.74, similar to the
0.73 survival probability observed in the amiodarone grol.lp.
At 2 years, the adjusted survival probability was 0.62 in
the control group, compared with 0.60 in the amiodarone
group.
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ilar to that of other patients with coronary artery disease,
when differences in baseline characteristics are taken into
account. However, patientswith life-threatening ventricular
arrhythmias complicating coronary artery disease have a
poor prognosis that is determined by the degree of myo-
cardialdysfunction and theextentof coronary arterydisease.
We are grateful to Cristy Vollmar for secretarial assistance in preparation
of the manuscript.
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